Uji Potensi Amikasin dan Rifampisin terhadap Pertumbuhan Rapidly Growing Mycobacterium

• Main Authors: , ADELIA ULYA RACHMAN, , dr. Praseno, Sp. MK
• Format: Theses and Dissertations NonPeerReviewed
• Published: [Yogyakarta] : Universitas Gadjah Mada 2014
• Subjects: ETD
• Online Access: https://repository.ugm.ac.id/127789/; http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=68072
• Institution: Universitas Gadjah Mada

Background : Treatment given to patient with lung disease due to rapidly growing mycobacterium (RGM) infection in Indonesia is still not appropriate. Antibiotic drugs for patients with lung disease due to RGM infection are different from patients with lung disease due to Mycobacterium tuberculosis. Rifampicin is an antibiotic commonly used for the treatment of tuberculosis, while amikacin is an aminoglycoside antibiotic used widespread as a therapeutic agent of bacterial infection which is expected to be active against rapidly growing mycobacterium. Objectives: To determine the effect of amikacin and rifampicin against RGM by in vitro method. Method : This study is an descriptive observational study using macrobroth dilution technique in vitro. The materials used were amikacin, rifampicin, and 7 RGM isolates collection of Department of Microbiology Faculty of Medicine Gadjah Mada University. Results : From 7 tested RGM isolates, 86% isolates are sensitive with MIC range <0.98 � 7.81 µg/µL and 14% isolates are resistant with MIC 23.44 µg/µL to amikacin, while 100% isolates are resistant to rifampicin with MIC range 5.91 - >15.75 µg/µL. Conclusion : RGM isolates are more sensitive to amikacin rather than rifampicin.